• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Norris SL, Carson S, Thakurta S, et al. Drug Class Review: Thiazolidinediones: Final Report Update 1 [Internet]. Portland (OR): Oregon Health & Science University; 2008 Aug.

Cover of Drug Class Review: Thiazolidinediones

Drug Class Review: Thiazolidinediones: Final Report Update 1 [Internet].

Show details

Appendix GOther (nonsystematic) reviews of thiazolidinediones

Author Year

AimsDatabases searched; Literature search dates; Other data sourcesEligibility criteriaNumber of trials/Number of patientsCharacteristics of identified articles: study designsCharacteristics of identified articles: populationsCharacteristics of identified articles: interventionsEfficacy and effectiveness resultsSubgroupsAdverse eventsComments
Lincoff, 2007To evaluate the effect of pio on ischemic CVD complications in diabetesDatabase of individual patient data from Takeda (manufacturers of pio)RCTs, double- blind, active- or placebo-controlled19
16,390 patients
RCTs onlyDiabetesTZD compared with a variety of comparators and placeboNRAge, sex, BMI, study duration, control therapyPrimary composite endpoint (death, nonfatal MI, nonfatal stroke): HR 0.82 (95% CI, 0.72 – 0.94), P =0.005; for placebo only trials HR 0.09 (95% CI, 0.01 – 0.84)
MI: HR 0.81 (95% CI, 0.64 – 1.02) Stroke: HR 0.80 (95% CI, 0.62 – 1.04) Serious heart failure: HR 1.41 (95% CI, 1.14 – 1.76)

NSD between sexes, age >or< 65y, or BMI< or > 30 mg/m2
Not a systematic review
Nissen, 2007To assess the effect of rosiglitazone on cardiovascular outcomesFDA web-site, a clinical trials registry maintained by GlaxoSmithKline, search of the published literature; 2 large trials included from the published literature; no information provided on additional searching of bibliographic databasesRCTs, similar duration of treatment in all groups, >24 weeks duration, outcome data on MI and death from CVD causes42
RCTs onlyLargely type 2 diabetes; also prediabetes, psoriasis, Alzheimer’s diseaseRosi compared with a variety of comparators and placeboNRNRMI, OR: 1.43 (95% CI, 1.03 – 1.98) Death from cardiovascular causes, OR: 1.64 (95% CI, 0.98 – 2.74).Not a systematic review
Paudwal, 2005To review the evidence for the prevention of type 2 diabetes by pharmacological therapiesMedline, EMBASE, Cochrane controlled Trials Register (inception date to 6/2004)RCTS and cohort studies with relevant data and an intention-to- treat analysis2 (for TZDs)
RCTs and cohort studies with TZD compared to placebo or control groupBoth studies examined troglitazoneBoth studies examined troglitazoneNot relevant (troglitazone)NRNot relevant (troglitazone)Not relevant (troglitazone)

Abbreviations: ACC, American College of Cardiology; AEs, adverse events; ADA, American Diabetes Association; AHA, American Heart Association; CHF, congestive heart failure; CVD, cardiovascular disease; DM2, type 2 diabetes mellitus; m, month(s); MI, myocardial infarction; NR, not reported; NSD, no significant difference; OR, odds ratio; PCI, percutaneous coronary intervention; pio, pioglitazone; RCTs, randomized controlled trials; rosi, rosiglitazone; RR, relative risk; SU, sulfonylurea; TVR, target vessel revascularization; TZD, thiazolidinedione; w, week(s); y, year(s).

Copyright © 2008, Oregon Health & Science University, Portland, Oregon.
Bookshelf ID: NBK10737
PubReader format: click here to try


  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (1.6M)

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...